|
310 Beiträge ausgeblendet. |
|
Cashentwicklung im Auge behalten
"AVEO believes that its $20.4 million in cash, cash equivalents, and marketable securities at the end of Q3 2018 and the additional $8.4 million raised from sales under its sales agreement with Leerink in October and November 2018 would allow it to fund planned operations into the second quarter of 2019 "
investor.aveooncology.com/news-releases/...sults-and-provides
FOTIVDA Zulassungsantrag verschoben
www.aveooncology.com/wp-content/uploads/...pdate-20190131.pdf
https://ec.europa.eu/transparency/regdoc/...NUMBER&sortOrder=DESC
25 Mio. $ Offering
seekingalpha.com/news/...a-24-percent-pricing-equity-offering
aus dem letzten Filling "The original Form 4, filed on June 13, 2019, is being amended by this Form 4 amendment solely to correct an administrative error, which misstated that Dr. Robert Young is the President and CEO of the Company. Dr. Young is a non-executive director of the Company."
am 30.09.2019 in Barcelona
https://cslide.ctimeetingtech.com/esmo2019/...tivozanib&r=st%7E13
Zahlen für Q3/19
investor.aveooncology.com/news-releases/...esults-and-provides
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
49 | Aveo Oncology - geht da was? | Balu4u | Vassago | 19.01.23 10:27 | ||
4 | 335 | Aveo Pharmaceuticals Next Hit ? | MasterbrokerUSA | twotto | 25.04.21 03:03 |